Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease

Fig. 1

Proportion of SGLT2 inhibitor use by the number of the associated factors. The associated factors are younger age (< 70 years), increased body mass index (≥ 25 kg/m2), and increased hemoglobin A1c levels (≥ 7.0% [52 mmol/mol]). Error bars indicate 95% confidence intervals. SGLT2, sodium-glucose co-transporter 2

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840